Conference Coverage

VIDEO: Pills alone not the answer for pain management


 

EXPERT ANALYSIS FROM CCR 18

SANDESTIN, FLA. – More than ever, clinicians need to rely on a multimodal approach to pain management, Katherine Galluzzi, DO, said at the annual Congress of Clinical Rheumatology.

In the era of opioid addiction – in which she said physicians have sometimes been unfairly vilified – pharmaceutical options are limited not only by the threat of abuse but also by governmental regulation, explained Dr. Galluzzi, chair of geriatrics at the Philadelphia College of Osteopathic Medicine.

“This is what we have, this is what we need to do,” Dr. Galluzzi said. “This impacts the quality of life, and patients need to begin providing self-care. It’s not going to come in the form of a pill. It has to be a commitment between the patient and the physician.”

The Centers for Medicare & Medicaid Services are proposing a new limit on opioid prescriptions for Medicare recipients – a maximum of 90 morphine mg equivalents per day for no more than 7 days. That will affect older people, who are most likely to be in need of pain management, she said. Those on hospice care and experiencing certain cancer pain will be exempt, she noted in an interview.

Concerns about addiction to drugs such as gabapentin and benzodiazepines might make these therapies less of an option in coming years, Dr. Galluzzi added.

Risk evaluation and mitigation strategy training is an important tool for helping physicians weigh the benefits and the risks of opioid prescriptions. Dr. Galluzzi particularly suggests enrolling in a 3-4 hour, in-person program, saying that it’s well worth the time.

“If you haven’t done a risk assessment and mitigation strategies course and you’re an opioid prescriber,” she said, “I highly recommend that you do that.”

Recommended Reading

MDedge Daily News: Can a nasal spray reverse suicidality?
MDedge Rheumatology
MDedge Daily News: Physician burnout needs more than yoga
MDedge Rheumatology
MDedge Daily News: Which nonopioids are ripe for abuse?
MDedge Rheumatology
FDA advisory committee votes to recommend update to celecoxib safety labeling
MDedge Rheumatology
Beware nonopiate meds with high street value
MDedge Rheumatology
MDedge Daily News: Lupus is quietly killing young women
MDedge Rheumatology
Constipation on opioids? Follow these three steps to ID the true cause
MDedge Rheumatology
MDedge Daily News: How to handle opioid constipation
MDedge Rheumatology
TissueGene-C effects on knee OA seen at 3 years
MDedge Rheumatology
Legalization of marijuana debate moving away from medical need
MDedge Rheumatology